<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722120</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2016-2272</org_study_id>
    <nct_id>NCT04722120</nct_id>
  </id_info>
  <brief_title>Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC</brief_title>
  <official_title>Low Contrast Agent and Radiation Dose Protocol for Liver CT Using IQon Spectral CT and IR Algorithm in Patients Who Received RFA for HCC: Prospective, Randomized, Single Blinded - Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test non-inferiority of spectral CT with low contrast agent&#xD;
      and low radiation dose, compare to conventional liver CT in surveillance of hepatocellular&#xD;
      carcinoma (HCC) in high-risk patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate quantitative and qualitative image quality and clinical feasibility of low&#xD;
      monoenergetic images of dual-energy spectral CT with simultaneous dose reduction of contrast&#xD;
      agent and radiation in participants at high-risk for HCC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Participants, investigators, and outcome assessors were all masked to the allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity for detection HCC</measure>
    <time_frame>12 months after last patient's image work up</time_frame>
    <description>diagnostic performance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative image quality analysis</measure>
    <time_frame>Immediate after study enrollement</time_frame>
    <description>Contrast-to-Noise</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Conventional liver CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Underwent conventional liver CT on HCC high-risk patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectral CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Underwent spectral liver CT with 30% lower radiation dose and 20% contrast media on HCC high-risk patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low radiation dose CT</intervention_name>
    <description>Underwent spectral CT with 30% lower radiation dose</description>
    <arm_group_label>Spectral CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional CT (radiation)</intervention_name>
    <description>Underwent spectral CT without change of radiation.</description>
    <arm_group_label>Conventional liver CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low contrast dose CT</intervention_name>
    <description>Underwent spectral CT 20% lower dose contrast media.</description>
    <arm_group_label>Spectral CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional CT (contrast agent)</intervention_name>
    <description>Underwent spectral CT without change of contrast media doses.</description>
    <arm_group_label>Conventional liver CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Tumor marker (aFP, PIVKA) elevation&#xD;
&#xD;
          -  Nodular lesion on USG&#xD;
&#xD;
          -  Received RFA for HCC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensitivity at iodine&#xD;
&#xD;
          -  GFR under 30&#xD;
&#xD;
          -  BMI over 30&#xD;
&#xD;
          -  Nursing or pregnant women&#xD;
&#xD;
          -  enrolled the other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

